Northwest Biotherapeutics, Inc. · OTC:NWBO

Northwest Biotherapeutics — Brain Tumor Biotech Summit 2013

24 slides from Northwest Biotherapeutics's conference presentation, Jun 7, 2013

  1. Slide 1: Dendritic Cell-Based Immunotherapies for Brain Tumors

    Dendritic Cell-Based Immunotherapies for Brain Tumors Brain Tumor Biotech Summit June 7, 2013

  2. Slide 2: Disclaimer

    Disclaimer Certain statements made in this presentation are “forward-looking statements” of NWBT as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this presentation that address activities, events or developments that

  3. Slide 3: Company and Portfolio Overview

    Company and Portfolio Overview • NWBio is a US-based biotechnology company with a European subsidiary located in Germany • NWBio’s portfolio comprises living cell, active immunotherapy products for the treatment of cancer • The company’s technology platform is based around autologous dendritic cells

  4. Slide 4: DCVax Clinical Trial Options

    DCVax Clinical Trial Options Cancer Diagnosis Resectable Not Resectable DCVax-L DCVax-Direct Protocol 020221 Protocol 050012 •For new GBM •For solid tissue tumors •For solid tissue tumors with brain metatases 4

  5. Slide 5: DCVax-L Clinical Trials in Patients with Glioblastoma multiforme

    DCVax®-L Clinical Trials In Patients with Glioblastoma multiforme

  6. Slide 6: DCVax-L Clinical Development

    DCVax-L Clinical Development First Phase I/II trial in GBM brain cancer Second Phase 2000-021 I/II trial in GBM Non- Blinded, randomized, controlled brain cancer blinded 2003-061 , rando m-ized Phase II Trial Phase 2007 I/II trial in ovarian cancer 2000 01 02 03 04 05 06 07 08 09 10 11 12 FDA approv

  7. Slide 7: Phase III Trial Design

    Phase III Trial Design • Multi-center, double blind, placebo controlled with cross-over • ~300 patients, randomized 2:1 (treatment:placebo) • DCVax-L adjuvant to standard of care (surgery, radiation, Temodar®) • DCVax-L immunizations interspersed with adjuvant Temodar® • 10 immunizations (induction,

  8. Slide 8: International Expansion of Phase III trial

    International Expansion of Phase III trial • The Phase III clinical trial is approved by MHRA (UK) – German authorization is pending • King’s College Hospital, London, is now recruiting patients • Additional site preparations are underway in the UK and Germany • Fraunhofer IZI has obtained manufactu

  9. Slide 9: DCVax-L Phase III Trial – Projections

    DCVax-L Phase III Trial – Projections • Recruitment to continue through Q2 of 2014 • Interim analyses (DSMB) late 2013 and early 2014 • Final analysis Q3 of 2014 9

  10. Slide 10: DCVax-Direct

    ih _\ NORTHWEST |. BIOTHERAPEUTICS DCVax-Direct® 10

  11. Slide 11: DCVax-Direct

    DCVax-Direct • DCVax-Direct: autologous, activated dendritic cells (DC) for intra-tumoral injection • Potential indications: all non-resectable (inoperable) solid tumors, such as: o Liver cancer o Liver metastases of colon cancer o Head and neck cancer o Esophageal cancer o Prostate cancer o Other c

  12. Slide 12: Manufacturing DCVax-Direct

    Manufacturing DCVax-Direct 12

  13. Slide 13: Tangential Flow Filtration (TFF)

    Tangential Flow Filtration (TFF) Filtration: To WASTE Inlet Filter vent Collection Unit Recirculation Product

  14. Slide 14: The “Activated DC” Concept

    The “Activated DC” Concept • The manufacturing system produces true immature DC • Activation of these DC starts with adding maturation agents to the bag • Full maturation takes 48 – 72 hours • Harvesting the DC prior to full maturation results in Activated DC • Activated DC: – Can still take up and

  15. Slide 15: Immature DC granularity and size

    Immature DC “granularity” Dendritic cells lymphocytes “size” 15

  16. Slide 16: Cytokine production DCVax-Direct

    Cytokine production DCVax-Direct 16

  17. Slide 17: DCVax-Direct Clinical Trials (1)

    DCVax-Direct Clinical Trials (1) • IND cleared by FDA for all solid tumor cancers, including metastatic to the brain if there is still an injectable lesion below the neck • Phase I/II combined trial -- Part I: dose-finding -- Part II: efficacy • First site scheduled to open for recruitment soon • Th

  18. Slide 18: DCVax-Direct: Striking Pre-Clinical Results

    DCVax®-Direct: Striking Pre-Clinical Results Tumor clearance on same side of body after direct injection in animal studies 250 250 Tum or Siz e (m m 2) Tum or S ize (m m 2) 200 200 + chemo 150 150 partially only 100 100 activated 50 50 DCs 0 0 0 7 14 21 28 35 42 0 7 14 21 28 35 42 Day Post Tumor Ino

  19. Slide 19: DCVax-Direct: Striking Pre-Clinical Results

    DCVax®-Direct: Striking Pre-Clinical Results Tumor clearance on opposite side of body after direct injection in animal studies 250 250 200 + Tumor Size (mm2) 200 chemo 150 partially Tumor Size (mm2) only 150 100 activated 100 DCs 50 50 0 0 7 14 21 28 35 42 0 0 7 14 21 28 35 42 Day Day 250 250 200 +

  20. Slide 20: Intra-tumoral Injection: Observations

    Intra-tumoral Injection: Observations • Intra-tumoral injection is best preceded by some form of other cytoreductive therapy • Intra-tumoral injection of activated DC results in dramatic enhancement in efficacy:  Eradication of tumors injected  Eradication of contralateral non-injected tumors Obse

  21. Slide 21: Acknowledgments

    Acknowledgments NORTHWEST BIOTHERAPEUTICS DCVAX-L PHASE III INVESTIGATORS Linda Powers AND SITE PERSONNEL Les Goldman Anthony Maida COGNATE BIOSERVICES Alton Boynton Meghan Swardstrom Julie McEarchern UCLA Linda Liau Robert Prins 21

  22. Slide 22: Appendix

    it |). NORTHWEST | BIOTHERAPEUTICS Appendix 22

  23. Slide 23: Newly Diagnosed GBM: Progression Free Survival

    Newly Diagnosed GBM: Progression Free Survival 1.0 0.9 “P value” = 0.00001 (i.e., 1 in 100,000 probability that 0.8 these trial results were random) Proportion not progressed 0.7 0.6 Patients 0.5 treated with 0.4 DCVax®-L 0.3 Matched patients 0.2 treated at same hospital, with Standard of Care 0.1 8

  24. Slide 24: Newly Diagnosed GBM: Overall Survival

    Newly Diagnosed GBM: Overall Survival 1.0 P value = 0.0003 0.9 (i.e., 3 in 10,000 probability that these trial results were random) 0.8 Proportion surviving 0.7 0.6 0.5 Patients 0.4 treated with DCVax®-L 0.3 0.2 Matched patients 0.1 treated at same hospital, 17 36.4 with Standard of Care 0.0 0 20 40

Northwest Biotherapeutics — Brain Tumor Biotech Summit 2013 on 6ix